Keyphrases
Recurrent Glioblastoma
100%
Phase II Study
100%
Doxorubicin
100%
Photothermal Therapy
100%
Overall Survival
44%
Historical Controls
44%
Progression-free Survival
33%
Blood-brain Barrier
33%
Salvage Therapy
33%
Bevacizumab
33%
Adverse Events
11%
No Significant Difference
11%
Cox Proportional Hazards Model
11%
Salvage Chemotherapy
11%
Adverse Event Rates
11%
Brain Tumor
11%
Drug Delivery
11%
Survival Trends
11%
Blood-brain Barrier Permeability
11%
Progression Pattern
11%
Local Recurrence-free Survival
11%
IDH mutation
11%
Doxorubicin Treatments
11%
Peritumoral
11%
Antineoplastic Drugs
11%
MGMT Promoter
11%
Arms Control
11%
Pharmacology, Toxicology and Pharmaceutical Science
Glioblastoma
100%
Doxorubicin
100%
Progression Free Survival
80%
Overall Survival
80%
Blood-Brain Barrier
80%
Bevacizumab
60%
Adverse Event
40%
Chemotherapy
20%
Anticarcinogen
20%
Intracranial Tumor
20%
Biochemistry, Genetics and Molecular Biology
Doxorubicin
100%
Overall Survival
80%
Blood Brain Barrier
80%
Progression Free Survival
80%
Low Drug Dose
60%
Bevacizumab
60%
Promoter Region
20%
Neuroscience
Doxorubicin
100%
Blood Brain Barrier
80%
Bevacizumab
60%
Promoter Region
20%
Anticarcinogen
20%
Antineoplastic Drugs
20%
Intracranial Tumor
20%